← Back
Data updated: Mar 10, 2026
NATCO PHARMA
OncologyNeurologyGastroenterology
NATCO PHARMA is a generic drug manufacturer focused on Oncology, Neurology, Gastroenterology. Key products include AZACITIDINE.
1987
Since
39
Drugs
-
Trials
411
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
BOSENTAN 2026-02-17
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
FINASTERIDE 2026-01-26
Labeling
OLANZAPINE 2026-01-23
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 32%
3 drugs Phase 2: 1
Neurology 29%
3 drugs
Gastroenterology 19%
2 drugs
Infectious Disease 10%
1 drugs
Immunology 10%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease, Neurology
AbbVie big-pharma
Immunology, Oncology, Neurology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Immunology, Neurology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology
Active (18)
Discontinued (18)
BOSENTAN OLANZAPINE FINASTERIDE LETROZOLE MONTELUKAST SODIUM TERBINAFINE HYDROCHLORIDE PRAMIPEXOLE DIHYDROCHLORIDE IMATINIB MESYLATE DONEPEZIL HYDROCHLORIDE CITALOPRAM HYDROBROMIDE FLURBIPROFEN LEVOFLOXACIN NADOLOL AND BENDROFLUMETHIAZIDE CHLOROQUINE PHOSPHATE MODAFINIL GLYBURIDE (MICRONIZED) TICLOPIDINE HYDROCHLORIDE CLORPRES
Company Info
- First Approval
- 1987-02-09
- Latest
- 2025-11-05
- Applications
- 45
FDA Sponsor Names
NATCO PHARMANATCO PHARMA LTD